Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.
Kathleen "Cook" Uhl's early announcement that she will retire from the US FDA's Office of Generic Drugs allows the agency to pursue an alternative recruitment strategy that could have the incoming and outgoing directors working together.
Uhl, who has run OGD since 2013, announced July 17 that she will retire from federal service in February. The...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
